Transparency Market Research, in a report titled “PSA Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019,” studies in depth the working, structure, scope, and dynamics of the global PSA testing market.

Prostate-specific antigen (PSA) is a protein produced by the prostate gland cells and a PSA test measures the amount of PSA present in a patient’s blood sample.

Get Sample Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2037

One of the primary factors driving the global PSA testing market is the increasing prevalence of prostate cancer around the world. The World Cancer Research Fund International states that in 2012, over 1.1 million cases of prostate cancer were recorded. An estimated 68% of all prostate cancer cases occurred in more developed countries, with North America recording the second highest incidence of prostate cancer. The World Cancer Research Fund International indicates that the rising availability of screening for PSA in men without any symptoms of the disease has resulted in the dramatic increase in the age-adjusted incidence of prostate cancer.

Another important factor propelling the PSA testing market is the growing acceptance of serum-based marker testing for the detection of prostate cancer. The sensitivity of the test has been enhanced in recent years by evaluating it in relation to other cancer-specific markers. The report states that PSA testing may lead to the risk of over-diagnosis and overtreatment, a factor that challenges the growth of the global PSA testing market.

The PSA testing market is segmented on the basis of clinical test and geography. By clinical test, the PSA testing market is categorized into prostate-specific antigen reverse transcription-polymerase chain reaction assays, free prostate-specific antigen assays, prostate-specific antigen values, and complexed prostate-specific antigen assays.

By geography, the PSA testing market is divided into Europe, North America, Asia Pacific, and Rest of the World. Owing to the high rate of prostate cancer in the regions, North America and Europe form the largest markets for PSA testing. Prostate cancer is the most common type of cancer among men in these regions. According to the Centers for Disease Control and Prevention, an estimated 177,489 men in the US alone were diagnosed with prostate cancer in 2012. Of these, an estimated 27,244 men succumbed from the disease.

The growing incidence of prostate-related disorders is also driving several countries in Latin America, Asia Pacific, and the Middle East and Africa.

The top players competing in the global PSA testing market include GlaxoSmithKline PLC, Endocare, Inc., Bristol-Myers Squibb Company, Beckman Coulter, Inc., Merck & Company, Inc., Sanofi-aventis SA, Abbott Laboratories, Inc., GE Healthcare, Boston Scientific Corporation, AstraZeneca PLC, Urologix, Inc., Medtronic, Inc., Bayer AG, and Boehringer Ingelheim GmbH. These players have been profiled in the PSA testing market report based on several key attributes such as company overview, business strategies, financial performance, and recent developments.

Full Research Report on Global PSA Testing Market:
http://www.transparencymarketresearch.com/psa-testing-market.html